Logo image of BCRX

BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Fundamental Analysis

NASDAQ:BCRX - Nasdaq - US09058V1035 - Common Stock - Currency: USD

9.21  -0.18 (-1.92%)

After market: 9.25 +0.04 (+0.43%)

Fundamental Rating

3

Overall BCRX gets a fundamental rating of 3 out of 10. We evaluated BCRX against 572 industry peers in the Biotechnology industry. BCRX may be in some trouble as it scores bad on both profitability and health. BCRX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BCRX had negative earnings in the past year.
In the past year BCRX has reported a negative cash flow from operations.
BCRX had negative earnings in each of the past 5 years.
In the past 5 years BCRX always reported negative operating cash flow.
BCRX Yearly Net Income VS EBIT VS OCF VS FCFBCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

BCRX has a better Return On Assets (-25.20%) than 73.00% of its industry peers.
Industry RankSector Rank
ROA -25.2%
ROE N/A
ROIC N/A
ROA(3y)-40.02%
ROA(5y)-47.36%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCRX Yearly ROA, ROE, ROICBCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

BCRX's Gross Margin of 98.06% is amongst the best of the industry. BCRX outperforms 97.51% of its industry peers.
In the last couple of years the Gross Margin of BCRX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BCRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y0.21%
BCRX Yearly Profit, Operating, Gross MarginsBCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

BCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BCRX has more shares outstanding than it did 1 year ago.
BCRX has more shares outstanding than it did 5 years ago.
BCRX has a worse debt/assets ratio than last year.
BCRX Yearly Shares OutstandingBCRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
BCRX Yearly Total Debt VS Total AssetsBCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

BCRX has an Altman-Z score of -2.54. This is a bad value and indicates that BCRX is not financially healthy and even has some risk of bankruptcy.
BCRX has a Altman-Z score (-2.54) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.54
ROIC/WACCN/A
WACC8.49%
BCRX Yearly LT Debt VS Equity VS FCFBCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

BCRX has a Current Ratio of 2.78. This indicates that BCRX is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.78, BCRX is not doing good in the industry: 68.74% of the companies in the same industry are doing better.
A Quick Ratio of 2.73 indicates that BCRX has no problem at all paying its short term obligations.
BCRX has a Quick ratio of 2.73. This is in the lower half of the industry: BCRX underperforms 67.14% of its industry peers.
Industry RankSector Rank
Current Ratio 2.78
Quick Ratio 2.73
BCRX Yearly Current Assets VS Current LiabilitesBCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.79% over the past year.
BCRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 29.92%.
Measured over the past years, BCRX shows a very strong growth in Revenue. The Revenue has been growing by 74.13% on average per year.
EPS 1Y (TTM)46.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.16%
Revenue 1Y (TTM)29.92%
Revenue growth 3Y165.04%
Revenue growth 5Y74.13%
Sales Q2Q%34.98%

3.2 Future

Based on estimates for the next years, BCRX will show a very strong growth in Earnings Per Share. The EPS will grow by 26.27% on average per year.
The Revenue is expected to grow by 19.27% on average over the next years. This is quite good.
EPS Next Y63.51%
EPS Next 2Y38.14%
EPS Next 3Y31.91%
EPS Next 5Y26.28%
Revenue Next Year37.22%
Revenue Next 2Y28.98%
Revenue Next 3Y23.73%
Revenue Next 5Y19.27%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BCRX Yearly Revenue VS EstimatesBCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
BCRX Yearly EPS VS EstimatesBCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BCRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCRX Price Earnings VS Forward Price EarningsBCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCRX Per share dataBCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as BCRX's earnings are expected to grow with 31.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.14%
EPS Next 3Y31.91%

More info and screens

0

5. Dividend

5.1 Amount

BCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCRYST PHARMACEUTICALS INC

NASDAQ:BCRX (2/21/2025, 8:02:57 PM)

After market: 9.25 +0.04 (+0.43%)

9.21

-0.18 (-1.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2024-11-04/bmo
Earnings (Next)02-24 2025-02-24/bmo
Inst Owners80.14%
Inst Owner Change-97.83%
Ins Owners1.42%
Ins Owner Change16.92%
Market Cap1.91B
Analysts82.35
Price Target15.58 (69.16%)
Short Float %8.64%
Short Ratio7.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)29.87%
Min EPS beat(2)-6.5%
Max EPS beat(2)66.23%
EPS beat(4)2
Avg EPS beat(4)17.05%
Min EPS beat(4)-12.5%
Max EPS beat(4)66.23%
EPS beat(8)4
Avg EPS beat(8)-3.33%
EPS beat(12)7
Avg EPS beat(12)5.43%
EPS beat(16)8
Avg EPS beat(16)-0.33%
Revenue beat(2)2
Avg Revenue beat(2)5.53%
Min Revenue beat(2)2.03%
Max Revenue beat(2)9.02%
Revenue beat(4)4
Avg Revenue beat(4)4.76%
Min Revenue beat(4)1.74%
Max Revenue beat(4)9.02%
Revenue beat(8)5
Avg Revenue beat(8)1.88%
Revenue beat(12)5
Avg Revenue beat(12)0.26%
Revenue beat(16)8
Avg Revenue beat(16)6.95%
PT rev (1m)3.07%
PT rev (3m)4.35%
EPS NQ rev (1m)21.07%
EPS NQ rev (3m)21.07%
EPS NY rev (1m)4.3%
EPS NY rev (3m)4.87%
Revenue NQ rev (1m)1.28%
Revenue NQ rev (3m)1.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.62
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS1.99
BVpS-2.26
TBVpS-2.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.06%
FCFM N/A
ROA(3y)-40.02%
ROA(5y)-47.36%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y0.21%
F-Score3
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 73.94%
Cap/Sales 0.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.78
Quick Ratio 2.73
Altman-Z -2.54
F-Score3
WACC8.49%
ROIC/WACCN/A
Cap/Depr(3y)177.05%
Cap/Depr(5y)129.28%
Cap/Sales(3y)0.89%
Cap/Sales(5y)1.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.16%
EPS Next Y63.51%
EPS Next 2Y38.14%
EPS Next 3Y31.91%
EPS Next 5Y26.28%
Revenue 1Y (TTM)29.92%
Revenue growth 3Y165.04%
Revenue growth 5Y74.13%
Sales Q2Q%34.98%
Revenue Next Year37.22%
Revenue Next 2Y28.98%
Revenue Next 3Y23.73%
Revenue Next 5Y19.27%
EBIT growth 1Y62.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year117.27%
EBIT Next 3Y50.03%
EBIT Next 5YN/A
FCF growth 1Y67.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.31%
OCF growth 3YN/A
OCF growth 5YN/A